Cartesian Therapeutics (RNAC) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 12, 2026, with virtual participation available to shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 11, 2026.

Voting matters and shareholder proposals

• Election of three directors: Michael Singer, Timothy A. Springer, and Patrick Zenner.

• Advisory vote on executive compensation (say-on-pay) for named executive officers.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Provision for other business to be transacted as may properly come before the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director nominees and auditor ratification.